Invited review: Cardiac valvular pathology: Comparative pathology and animal models of acquired cardiac valvular diseases

Toxicologic Pathology

Volumn 36, Issue 2, 2008, Pages 204-217

  Donnelly, Kevin B ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

5 HT; Animal model; Cardiac valve; Fenfluramine; Phentermine; Valvular disease; Valvular injury; Valvulopathy

Indexed keywords

AMPHETAMINE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BENFLUOREX; BROMOCRIPTINE; CABERGOLINE; DEXFENFLURAMINE; ERGOTAMINE; ERGOTAMINE DERIVATIVE; FENFLURAMINE; METHYSERGIDE; PERGOLIDE; PERGOLIDE MESILATE; PHENTERMINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ANATOMY; ANTIPHOSPHOLIPID SYNDROME; AORTA ATHEROSCLEROSIS; AORTA VALVE REGURGITATION; BACTERIAL ENDOCARDITIS; CARCINOID SYNDROME; CARDIOMYOPATHY; COMPARATIVE STUDY; DEVELOPMENTAL BIOLOGY; DISEASE ASSOCIATION; DISEASE MODEL; HEART; HEART VALVE; HEMODYNAMICS; HUMAN; MARFAN SYNDROME; MITRAL VALVE REGURGITATION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VALVULAR HEART DISEASE; ANIMAL; CHEMICALLY INDUCED DISORDER; DOG; PATHOLOGY; RAT; SPECIES DIFFERENCE;

ANIMALIA;

ANIMALS; APPETITE DEPRESSANTS; DISEASE MODELS, ANIMAL; DOGS; FENFLURAMINE; HEART VALVE DISEASES; HEART VALVES; HUMANS; PHENTERMINE; RATS; SEROTONIN UPTAKE INHIBITORS; SPECIES SPECIFICITY;

EID: 42149164919     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623307312707     Document Type: Review

References (116)

1. Aikawa, E., Whittaker, P., Farber, M., Mendelson, K., Padera, R.F., Aikawa, M., et al (2006). Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation 113, 1344-52.
2. Aird, W.C. (2007). Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 100, 158-73.
3. Aliev, G., and Burnstock, G. (1998). Watanabe rabbits with heritable hypercholesterolaemia: a model of atherosclerosis. Histol Histopathol 13, 797-817.
4. Arciniegas, E., Sutton, A.B., Allen, T.D., and Schor, A.M. (1992). Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro. J Cell Sci 103, 521-35.
5. Armstrong, E.J., and Bischoff, J. (2004). Heart Valve Development: Endothelial cell signaling and differentiation. Circ Res 95, 459-70.
6. Barth, P.J., Koster, H., and Moosdorf, R. (2005). CD34+ fibrocytes in normal mitral valves and myxomatous mitral valve degeneration. Pathol Res Pract 201, 301-4.
7. Baseman, D.G., O'Suilleabhain, P.E., Reimold, S.C., Laskar, S.R., Baseman, J.G., and Dewey, R.B. (2004). Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63, 301-4.
8. Benjamin, E.J., Plehn, J.F., D'Agostino, R.B., Belanger, A.J., Comai, K., Fuller, D.L., et al (1992). Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med 327, 374-79.
9. Black, A., French, A.T., Dukes-McEwan, J., and Corcoran, B.M. (2005). Ultrastructural morphologic evaluation of the phenotype of valvular interstitial cells in dogs with myxomatous degeneration of the mitral valve. Am J Vet Res 66, 1408-14.
10. Bonow, R.O., Carabello, B.A., Kanu, C., de Leon, A.C., Faxon D.P., Freed, M.D., et al (2006). ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation 114, e84-231.
11. Boudoulas, H. (2003). Etiology of valvular heart disease. Expert Rev Cardiovasc Ther 1, 523-32.
12. Bratter, J., Gessner, I.H., and Rowland, N.E. (1999). Effects of prenatal co-administration of phentermine and dexfenfluramine in rats. Eur J Pharmacol 369, R1 - R3.
13. Braunwald, E. (1998). Valvular Heart Disease. In Harrison's Principles of Internal Medicine (A. S. Fauci, E. Braunwald, K. J. Isselbacher, J. D. Wilson, J. B. Martin, D. L. Kasper, et al, eds.). McGraw-Hill, New York.
14. Butany, J., Collins, M.J., El Demellawy, D., Nair, V., Israel, N., Leong, S.W., et al (2005). Morphological and clinical findings in 247 surgically excised native aortic valves. Can J Cardiol 21, 747-55.
15. Cannistra, A.J. (2005). Adult valvular heart disease: A practical approach. Prim Care 32, 1109-14.
16. Chamanza, R., Parry, N.M.A., Rogerson, P., Nicol, J.R., and Bradley, A.E. (2006). Spontaneous lesions of the cardiovascular system in purpose-bred laboratory nonhuman primates. Tox Path 34, 357-63.
17. Cimini, M., Bougher, D.R., Ronald, J.A., Aldington, L., and Rogers, K.A. (2005). Development of aortic valve sclerosis in a rabbit model of atherosclerosis: an immunohistochemical and histological study. J Heart Valve Dis 14, 365-75.
18. Connolly, H.M., Crary, J.L., McGoon, M.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D., et al (1997). Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337, 591-98.
19. Cuniberti, L.A., Stutzbach, P.G., Guevara, E., Yannarelli, G.G., Laguens, R.P., and Favaloro, R.R. (2006). Development of mild aortic valve stenosis in a rabbit model of hypertension. J Am Coll Cardiol 47, 2303-9.
20. Desmoulière, A., Chaponnier, C., and Gabbiani, G. (2005). Tissue repair, contraction, and the myofibroblast. Wound Repair Regen. 13, 7-12.
21. Drolet, M.C., Arsenault, M., and Couet, J. (2003). Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol 41, 1211-17.
22. Drolet, M.C., Roussel, E., Deshaies, Y., Couet, J., and Arsenault, M. (2006). A high fat/high carbohydrate diet induces aortic valve disease in C57BL/6J mice. J Am Coll Cardiol 47, 850-55.
23. Droogmans, S., Franken, P.R., Garbar, C., Weytjens, C., Cosyns, B., Lahoutte, T., et al (2007). In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 28, 2156-62.
24. Durbin, A.D., and Gotlieb, A.I. (2002). Advances towards understanding heart valve response to injury. Cardiovascular Pathology 11, 69-77.
25. Eisenberg, L.M., and Markwald, R.R. (1995). Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ Res 17: 1-13.
26. Elangbam, C.S., Colman, K.A., Lightfoot, R.M., Tyler, R.D., and Wall, H.G. (2002). Endocardial myxomatous change in Harlan Sprague-Dawley rats (Hsd:S-D) and CD-1 mice: its microscopic resemblance to drug-induced valvulopathy in humans. Toxicol Pathol 30, 483-91.
27. Elangbam, C.S., Wehe, J.G., Barton, J.C., Krull, K.L., Nyska, A., Crabbs, T., et al (2006). Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in the heart valves of Sprague-Dawley rats with spontaneous mitral valvulopathy-a possible exacerbation by dl-amphetamine sulfate in Fischer 344 rats ? Exp Toxicol Pathol 58, 89-99.
28. FDA News (2007). FDA Announces Voluntary Withdrawal of Pergolide Products. Drug Industry Daily, 6 (64) from FDA News website: http://www.fdanews.com/newsletters.
29. Fitzgerald, L.W., Burn, T.C., Brown, B.S., Patterson, J.P. Corjay, M.H., Valentine, P.A., et al (2000). Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57, 75-81.
30. Fondard, O., Detaint, D., Iung, B., Choquex, C., Aidle-Biasset, H., Jarraya, M., et al (2005). Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors. Eur Heart J 26, 1333-41.
31. Freed, L.A., Levy, D., Levine, R.A., Larson, M.G., Evans, J.C., Fuller D. L., et al (1999). Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med 341, 1-7.
32. Gaash, W.H., Zile, M.R., Hoshino, P.K., Weinberg, E.O., Rhodes, D.R., and Apstein, C.S. (1990). Tolerance of the hypertrophic heart to ischemia: studies in compensated and failing dog hearts with pressure overload and hypertrophy. Circulation 81, 1644-53.
33. Gardin, J.M., Schumacher, D., Constantine, G., Davis, K.D., Leung, C., and Reid, C.L. (2000). Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 283, 1703-9.
34. Gustafsson, B.I., Tommeras, K., Nordrum, I., Loennechen, J.P., Brunsvik, A., Solligard, E., Fossmark, R., Bakke, I., et al (2005). Long-term serotonin administration induces heart valve disease in rats. Circulation 111, 1517-22.
35. Harleman, J.H., Joseph, E.C., Eden, R.J., Walker, T.F., Major, I.R., and Lamb, M.S. (1986). Cardiotoxicity of a new inotrope/vasodilator drug (SK&F 94120) in the dog. Arch Toxicol 59, 51-55.
36. Hauck, A.J., Edwards, W.D., Danielson, G.K., Mullany, C.J., and Breshahan, D.R. (1990). Mitral and aortic valve disease associated with ergotamine therapy for migraine. Arch Pathol Lab Med 114, 62-64.
37. Hauso, O., Gustafsson, B.I., Loennechen, J.P., Stunes, A.K., Nordrum, I., and Waldum, H.L. (2007). Long-term serotonin effects in the rat are prevented by terguride. Regul Pept 143, 39-46.
38. Hendrikx, M., Van Dorpe, J., Flameng, W., and Daenen, W. (1996). Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 5, 235-37.
39. Hinton, R.B., Lincoln, J., Deutsch, G.H., Osinska, H., Manning, P.B., Benson, et al (2006). Extracellular matrix remodelling and organization on developing and diseased aortic valves. Circ Res 98, 1431-38.
40. Hofmann, C., Penner, U., Dorow, R., Pertz, H.H., Jahnichen, S., Horowski, R., et al (2006). Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reactions reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 29, 80-86.
41. Hughes, B.R., Chahoud, G., and Mehta, J.L. (2005). Aortic stenosis: is it simply a degenerative process or an active atherosclerotic process ? Clin Cardiol 28, 111-14.
42. Isaacs, K.R., Joseph, E.C., and Betton, G.R. (1989). Coronary vascular lesions in dogs treated with phosphodiesterase III inhibitors. Toxicol Pathol 17, 153-63.
43. Jian, B., Xu, J., Connolly, J., Savani, R.C., Narula, N., Liang, B., and Levy, R.J. (2002). Serotonin mechanisms in heart valve disease I. Am J Pathol 161, 2111-21.
44. Jick, H., Vasilakis, C., Weinrauch, L.A., Meier, C., Jick, S.S., and Derby, L.E. (1998). A Population-Based Study of Appetite-Suppressant Drugs and the Risk of Cardiac-Valve Regurgitation. N Engl J Med 339, 719-24.
45. Kaartinen, V., and Warburton, D. 2003. Fibrillin controls TGF-β activation. Nat Genet 33, 331-32.
46. Keenan, C.M., and Vidal, J.D. (2006). Standard morphologic evaluation of the heart in the laboratory dog and monkey. Toxicol Pathol 34, 67-74.
47. Khan, M.A., Herzog, C.A., St Peter, J.V., Harley, G.G., Madlon-Kay, R., Dick, C.D., et al (1998). The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite suppressant drugs. N Engl J Med 339, 713-18.
48. Lee, C.T., Zhao, Y.D., Courtman, D.W., and Stewart, D.J. (2000). Abnormal aortic valve development in mice lacking endothelial nitric oxide synthase. Circulation 101, 2345-48.
49. Leszczynski, P., Straburzynska-Migaj, E., Korczowska, I., Lacki, J.K., and Mackiewicz, S. (2003). Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies. Clin Rheumatol 22, 405-8.
50. Lev, S., and Shoenfeld, Y. (2002). Cardiac valvulopathy in the antiphospholipid syndrome. Clin Rev Allergy Immunol 23, 341-48.
51. Libman, E., and Sachs, B. (1924). Hitherto undescribed form of valvular and mural endocarditis. Arch Int Med 33, 701-37.
52. Marron, K., Yacoub, M.H., Polak, J.M., Sheppard, M.N., Fagan, D., Whitehead, B.F., et al (1996). Innervation of human atrioventricular and arterial valves. Circulation 94, 368-75.
53. Mast, S., Gersing, K., Anstrom, K., Krishnan, K., Califf, R., and Jollis, J. (2001). Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. Am J Cardiol 87, 989-93.
54. McDonald, P.C., Wilson, J.E., Gao, M., McNeill, S., Spinelli, J.J., Resenberg, F., et al (2002 a). The challenge of defining normality for human mitral and aortic valves. Geometrical and compositional analysis. Cardiovasc Pathol 11, 193-209.
55. McDonald, P.C., Wilson, J.E., Gao, M., McNeill, S., Spinelli, J.J., Williams, O.D., et al (2002 b). Quantitative analysis of human heart valves. Does anorexigen exposure produce a distinct morphological lesion? Cardiovasc Pathol 11, 251-62.
56. Mekontso-Dessap, A., Brouori, F., Pascal, O., Lechat, P., Hanoun, N., Lanfumey, L., et al (2006). Deficiency of the 5-Hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113, 181-89.
57. Messier, R.H., Bass, B.L., Aly, H.M., Jones, J.L., Domkowski, P.W., Wallace, R.B., et al (1994). Dual structural and functional phenotypes of the porcine aortic valve interstitial population: characteristics of the leaflet myofibroblast. J Surg Res 57, 1-21.
58. Mmwr (2006). Age-adjusted death rates for the five leading causes of death, United States, 2001-2004. Morbidity and Mortality Weekly Report 55, 1075.
59. Mohr, U., Dungworth, D.L., and Capen, C.C. (1992). Pathobiology of the Aging Rat. Washington, DC: ILSI Press.
60. Moller, J.E., Connolly, H.M., Rubin, J., Seward, J.B., Modesto, K., and Pellikka, P.A. (2003). Factors associated with progression of carcinoid heart disease. N Eng J Med 348, 1005-15.
61. Morales, A.R., Romanelli, R., Boucek, R.J., Tate, L.G., Alvarez, R.T., and Davis, J.T. (1992). Myxoid heart disease. Hum Pathol 23, 129-37.
62. Musunuru, S., Carpenter, J.E., Sippel, R.S., Kunnimalaiyaan, M., and Chen, H. (2005). A mouse model of carcinoid syndrome and heart disease. J Surg Res 126, 102-5.
63. Ng, C.M., Cheng, A., Myers, L.A., Martinex-Murillo, F., Jie, C., Bedja, D., et al (2004). TGF-β dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 114, 1586-92.
64. Noize, P., Sauer, M., Bruneval, P., Moreau, M., Pathak, A., Bagheri, H., et al (2006). Valvular heart disease in a patient taking benfluorex. Fundam Clin Pharmacol 20, 577-78.
65. Otto, C.M., Lind, C.K., Kitzman, D.W., Gersh, B.J., and Siscovick, D.S. (1999). Association of aortic valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 341, 142-47.
66. Paranya, G., Vineberg, S., Dvorin, E., Kaushal, S., Roth, S.J., Rabkin, E., et al (2001). Aortic valve endothelial cells undergo transforming growth factor-beta-mediated and non-transforming growth factor-beta-mediated transdifferentiation in vitro. Am J Pathol 159, 1335-43.
67. Pedersen, H.D., and Haggstrom, J. (2000). Mitral valve prolapse in the dog: a model for mitral valve prolapse in man. Cardiovasc Res 47, 234-43.
68. Pinero, A., Marcos-Alberca, P., and Fortes, J. (2005). Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 353, 1976-77.
69. Quinn, A., Kosanke, S., Fischetti, V.A., Factor, S.M., and Cunningham, M.W. (2001). Induction of autoimmune valvular heart disease by recombinant streptococcal M protein. Infect Immunol 69, 4072-78.
70. Rabkin, E., Aikawa, M., Stone, J.R., Fukumoto, Y., Libby, P., and Schoen, F.J. (2001). Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodelling in myxomatous heart valves. Circulation 104, 2525-30.
71. Rafel Ribera, J., Casanas Munoz, R., Anguera Ferrando, N., Batalla Sahun, N., Castro Cels, A., and Pujadas Capmany, R. (2003). Valvular heart disease associated with benfluorex. Rev Esp Cardiol 56, 215-16.
72. Rajamannan, N.M., Caplice, N., Anthikad, F., Sebo, T.J., Orszulak, T.A., Edwards, W.D., et al (2001 a). Cell proliferation in carcinoid valve disease: A mechanism for serotonin effects. J Heart Valv Dis 10, 827-31.
73. Rajamannan, N.M., Sangiorgi, G., Springett, M., Arnold, K., Mohacsi, T., Spagnoli, L.G., et al (2001 b). Experimental hypercholesterolemia induces apoptosis in aortic valve. J Heart Valve Dis 10, 371-74.
74. Rajamannan, N.M., Subramaniam, M., Rickard, D., Stock, S.R., Donovan, J., Springett, M., et al (2003). Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107, 2181-84.
75. Raman, S., Sparks, E., Boudoulas, H., and Wooley, C. (2003). Tricuspid valve disease: tricuspid valve complex perspective. Curr Prob Cardiol 27, 99-142.
76. Rayburn, W.F., Sienko, A.E., Gonzalez, C.L., Kupiec, T.C., Paulsen, A.L., and Stewart, J.D. (2000). Impact of antenatal exposure of mice to fenfluramine on cardiac development and long-term growth of the offspring. Drug Chem Toxicol 23, 419-31.
77. Redfield, M.M., Nicholson, W.J., Edwards, W.D., and Tajik, A.J. (1992). Valve disease associated with ergot alkaloid use: Echocardiographic and pathologic correlations. Ann Intern Med 117, 50-52.
78. Rippe, J., Fishbein, M.C., Carabello, B., Angoff, G., Collins, J.J., and Alpert, J.S. (1980). Primary myxomatous degeneration of cardiac valves. Clinical, pathological, haemodynamic, and echocardiographic profile. Br Heart J 44, 621-29.
79. Robinson, P., and Booms, P. (2001). The molecular pathogenesis of the Marfan syndrome. Cell Mol Life Sci 58, 1698-1707.
80. Rosenberg, C.A., Derman, G.H., Grabb, W.C., and Buda, A.J. (1983). Hypomastia and mitral-valve prolapse: evidence of a linked embryologic and mesenchymal dysplasia. N Engl J Med 309, 1230-32.
81. Rothman, R.B., Baumann, M.H., Savage, J.E., Rauser, L., McBride, A., Hufeisen, F.J., et al (2000). Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836-41.
82. Ruben, Z., Arceo, R.J., Bishop, S.P., Elwell, M.R., Kerns, W.D., Mesfin, G.M., et al (2000). Nonproliferative lesions in the heart and vasculature in rats. Washington, DC: STP / ARP / AFIP.
83. Rubin, G. (1992). Acquired Valvular Diseases. New York: Churchill Livingstone.
84. Rush, J.E. (2002). Chronic Valvular Heart Disease in Dogs. In Proceedings of the 26th Annual Waltham Diets/OSU Symposium for the Treatment of Small Animal Cardiology, pp. 1-7.
85. Sandusky, G.E. (1997). Pathogenesis and characterization of myocardial lesions caused by vasoactive compounds. In Comprehensive Toxicology (Bishop, S. P. and Kerns, W. D., eds.). Vol. 6. Amsterdam: Elsevier.
86. Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., and Garbe, E. (2007). Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356, 29-38.
87. Schneider, P. (1990). Hemodynamically induced heart lesions in the dog after administration of cardio-active substances. Exp Pathol 40, 155-68.
88. Schoen, F.J. (1997). Aortic valve structure-function correlations: Role of elastic fibers no longer a stretch of the imagination. J Heart Valve Dis 6, 1-6.
89. Schoen, F.J. (2005). Cardiac valves and valvular pathology. Update on function, disease, repair and replacement. Cardiovasc Pathol 14, 189-94.
90. Schoen, F.J. (2006). New frontiers in the pathology and therapy of heart valve disease. Cardiovasc Pathol 15, 271-79.
91. Schoen, F.J., and Edwards, W.D. (2001). Valvular Heart Disease: General Principles and Stenosis. In Cardiovascular Pathology (M. D. Sliver, A. I. Gotlieb, and F. J. Schoen, ed.). Philadelphia: Churchill Livingstone, pp. 402-42.
92. Schroeder, J.A., Jackson, L.F., Lee, D.C., and Camenisch, T.D. (2003). Form and function of developing heart valves: coordination by extracellular matrix and growth factor signaling. J Molec Med 81, 392-403.
93. Seghatol, F.F., and Rigolin, V.H. (2002). Appetite suppressants and valvular disease. Curr Opin Cardiol 486-92.
94. Serini, G., and Gabbiani, G. (1999). Mechanisms of myofibroblast activity and phenotypic modulation. Exp Cell Res 250.
95. Serratrice, J., Disdier, P., Habib, G., Viallet, F., and Weiller, P.J. (2002). Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10, 334-36.
96. Setola, V., Hufeisen, S.J., Grande-Allen, K.J., Vesely, I., Glennon, R.A., Blough, B., et al (2003). 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valve interstitial cells in vitro. Mol Pharmacol 63, 1223-29.
97. Silver, M.D., and Silver, M.M. (2001). Valvular Heart Disease: Conditions Causing Regurgitation. In Cardiovascular Pathology (M. D. Sliver, A. I. Gotlieb, and F. J. Schoen, ed.). Philadelphia: Churchill Livingstone, pp. 443-70.
98. Soler-Soler, J. (2000). Worldwide perspective of valve disease. J Heart Valve Dis 83, 721-25.
99. Steffee, C.H., Singh, H.K., and Chitwood, W.R. (1999). Histologic changes in three explanted native cardiac valves following use of fenfluramines. Cardiovasc Pathol 8, 245-53.
100. Stewart, B.F., Siscovick, D., and Lind, B.K. (1997). Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol 29, 630-34.
101. Stollerman, G.H. (1995). Rheumatic fever. In Harrison's Principles of Internal Medicine. 13 th ed. New York: McGraw-Hill.
102. Tanaka, K., Sata, M., Fukuda, D., Suematsu, Y., Motomura, N., Takamoto, S., et al (2005). Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol 46, 134-41.
103. Taylor, P.M., Batten, P., Brand, N.J., Thomas, P.S., and Yacoub, M.H. (2003). The cardiac valve interstitial cell. Int J Biochem Cell Biol 35, 113-18.
104. Veinot, J.P. (2006). Pathology of inflammatory native valvular heart disease. Cardiovasc Pathol 15, 243-51.
105. Veinot, J.P., and Walley, V.M. (2000). Focal and patchy cardiac valve lesions: A clinicopathological review. Can J Cardiol 16, 1489-1507.
106. Volmar, K.E., and Hutchins, G.M. (2001). Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med 125, 1555-61.
107. Wadden, T.A., Berkowitz, R.I., Silvestry, F., Vogt, R.A., St John Sutton, M.G., Stunkard, A.J., et al (1998). The fen-phen finale: a study of weight loss and valvular heart disease. Obes Res 6, 278-84.
108. Walker, G.A., Masters, K.S., Shah, D.N., Anseth, K.S. and Leinwand, L.A. (2004). Valvular myofibroblast activation by transforming growth factor-beta. Circ Res 95, 253-68.
109. Waller, E.A., and Kaplan, J. (2006). Pergolide-associated valvular heart disease. Comp Ther 32, 94-101.
110. Weiss, R.M., Ohashi, M., Miller, J.D., Young, S.G., and Heistad, D.D. (2006). Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 114, 2007-9.
111. Weissman, N.J., Tighe, J.F., Gottdiener, J.S., and Gwynne, J.T. (1998). An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 339, 725-32.
112. Weyman, A.E., and Scherrer-Crosbie, M. (2004). Marfan syndrome and mitral valve prolapse. J Clin Invest 114, 1543-64.
113. Xu, J., Jian, B., Chu, R., Lu, Z., Li, Q., Dunlop, J., et al (2002). Serotonin mechanisms in heart valve disease II. Am J Pathol 161, 2209-18.
114. Zadikoff, C., Rochon, P., and Lang, A. (2006). Cardiac valvulopathy associated with pergolide use (review). Can J Neurol Sci 33, 27-33.
115. Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., and Pezzoli, G. (2007). Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356, 39-46.
116. Zuetenhorst, J.M., Bonfrer, J.M.G.M., Korse, C.M. Bakker, R., Van Tinteren, H., and Taal, B.G. (2003). Carcinoid Heart Disease. Cancer 97, 1609-15.